ReviewMedicina (Kaunas, Lithuania)2023
Hidradenitis Suppurativa and JAK Inhibitors: A Review of the Published Literature.
Review in Medicina (Kaunas, Lithuania), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 47 citations in OpenAlex.
- Real-world experience with upadacitinib in hidradenitis suppurativa: efficacy and safety in patients with dermatological comorbidities.Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG · 2026Article
- The Role of Inflammatory Biomarkers in Disease Severity and Treatment Response across Psoriasis, Atopic Dermatitis, and Hidradenitis Suppurativa-A Narrative Review.Dermatology and therapy · 2026Review
- Article
- Cutaneous Manifestations and Dermatologic Adverse Events in IBD: A Clinical Update.Inflammatory bowel diseases · 2026Review
- Beneficial effects of upadacitinib on a subgroup of patients with atopic dermatitis and hidradenitis suppurativa: a multicenter, real-world retrospective study.Frontiers in immunology · 2026Observational
- Wide excision and latissimus dorsi flap reconstruction for advanced axillary hidradenitis suppurativa: a case series.Case reports in plastic surgery & hand surgery · 2026Article
- JAK Inhibitors for Treatment of SAPHO Syndrome: A Systematic Review of 72 Cases.ACR open rheumatology · 2025Review
- Severe Paradoxical Scalp Psoriasis Induced by Bimekizumab in a Young Multifailure Hidradenitis Suppurativa Patient.Dermatology and therapy · 2025Article
- Dual immunomodulator therapy with adalimumab and upadacitinib to treat recalcitrant hidradenitis suppurativa.JAAD case reports · 2025Article
- Bimekizumab for Hidradenitis Suppurativa from Trials to Real Life: A Review of the Published Literature.Clinical, cosmetic and investigational dermatology · 2025Review
- Hypergammaglobulinemia in Hidradenitis Suppurativa Patients: A New Emerging Association.Clinical, cosmetic and investigational dermatology · 2025Article
- Hidradenitis Suppurativa Cancer Risk: A Review of the Literature.Clinical, cosmetic and investigational dermatology · 2025Review
- Hidradenitis Suppurativa in Elderly Patients: Clinical and Therapeutical Outcomes-A Review of the Literature.Medicina (Kaunas, Lithuania) · 2024Review
- Biologics and Small Molecule Targeted Therapies for Pediatric Alopecia Areata, Psoriasis, Atopic Dermatitis, and Hidradenitis Suppurativa in the US: A Narrative Review.Children (Basel, Switzerland) · 2024Review
- Is there a surgical window of opportunity in hidradenitis suppurativa?International wound journal · 2024Article
- New treatment of pyoderma gangrenosum and hidradenitis suppurativa: A review.The Journal of dermatology · 2024Review
- Real-Time Experience of Abrocitinib for the Treatment of Mucous Membrane Pemphigoid: A Case Report.Patient preference and adherence · 2024Article
- Secukinumab for Severe Hidradenitis Suppurativa in a Patient on Haemodialysis: Efficacy and Safety on 300 mg Every 2 Weeks Administration - A Case Report.Clinical, cosmetic and investigational dermatology · 2024Article
- Long-Term Efficacy of Guselkumab in an Adolescent Hidradenitis Suppurativa Patients: A Case Report.Clinical, cosmetic and investigational dermatology · 2024Article
- SOCS1 and SOCS3 as key checkpoint molecules in the immune responses associated to skin inflammation and malignant transformation.Frontiers in immunology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.